Abstract
The use of SSRIs for depression in pregnancy remains a therapeutic challenge. Fetal exposure to maternal SSRIs have been implicated in the disruption of cognitive and physiologic domains during fetal development. The protein p11 (s100a10) interacts with the 5-HT1B (htr1b) serotonin (5-HT) receptor, regulating its localization to the cell surface. 5-HT signaling through this receptor modulates fetal brain axonal circuit formation. SSRI therapy has been shown to indirectly regulate p11 levels in the adult brain.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
